A New Leader Takes the Helm at PureTech Health

PureTech Health has a new boss. Robert Lyne is now the CEO. He's been with the company for a while. He was the interim CEO since July 2025. Before that, he was the Chief Portfolio Officer. He's got a lot of experience. He used to be the CEO of Arix Bioscience plc. He's worked in life science and venture capital for over ten years. Lyne is excited about his new role. He says PureTech has strong programs and a great team. He wants to build on what's already there. His first big task is to get funding for Celea Therapeutics. This is a new part of PureTech. They had a meeting with the FDA. It went well. They expect to close the deal by the first half of 2026. After that, PureTech will spend less money on running the company.Lyne also wants to focus on Gallop Oncology. This is another part of PureTech. They have good data from their tests. The program is moving to the next stage. Lyne wants to get funding for this too. He plans to make the company leaner. This means fewer people and less spending. He wants to be smart about where they put their money. He thinks this will make shareholders happy. Sharon Barber-Lui is the Interim Chair of the Board. She's happy with Lyne's appointment. She says he's a strong leader. He knows the business well. The Board likes his plan to focus on important things. They think he's the right person to lead PureTech. PureTech Health is a biotherapeutics company. They make medicines. They have a special way of doing things. They find good ideas and turn them into medicines. They've made dozens of medicines. Three of them are approved by the FDA. They want to help patients and make money for shareholders.